CD8A and non-small cell lung carcinoma: In patients with non-small cell lung cancer (NSCLC) an increased proliferation of CD8+ cytotoxic T-cells (CTL) in peripheral blood correlated with response to nivolumab therapy, whereas patients with progressive disease had no change in CTL proliferation or even a decrease [10,11].